Hepatitis D, Chronic: Clinical Trials

9 trials for Hepatitis D, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 9 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 39Completed 5, Active not recruiting 2, Not yet recruiting 1, Recruiting 1
Phase 21Recruiting 1

Follow Hepatitis D, Chronic: new trials by email Literature Review of Hepatitis D, Chronic trials Research Report on Hepatitis D, Chronic

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic
Phase 3Not yet recruitingShanghai HEP Pharmaceutical Co., Ltd.1502027-06-012026-10-28
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D
Phase 2 / Phase 3RecruitingMirum Pharmaceuticals, Inc.1202026-02-262026-10-27
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
Tobevibart, Elebsiran, Bulevirtide - Viral Hepatitis
Phase 3Active not recruitingVir Biotechnology, Inc.1502025-07-302026-07-13
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Tobevibart, Elebsiran - Viral Hepatitis
Phase 3Active not recruitingVir Biotechnology, Inc.1242025-03-122026-11-03
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Lonafarnib, Ritonavir - Hepatitis D, Chronic
Phase 3CompletedSoroka University Medical Center102021-05-152026-04-30
Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)
Bulevirtide - Chronic Hepatitis Delta
Phase 3CompletedGilead Sciences1502019-04-172025-08-22
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
peginterferon alfa-2a [Pegasys], placebo, tenofovir - Hepatitis D, Chronic
Phase 3CompletedHoffmann-La Roche502010-02-162019-01-14
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
Peginterferon alfa-2b (PegIntron, SCH 54031) - Hepatitis D, Chronic, Hepatitis B, Chronic
Phase 3CompletedMerck Sharp & Dohme LLC682005-12-012017-04-06
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
Pegylated Interferon (PEG-IFN) alfa-2a - Hepatitis D, Chronic
Phase 3CompletedHoffmann-La Roche312005-10-012016-08-26

Narrower conditions

Hepatitis D (4)  ·  Hepatitis (2)  ·  Hepatitis B (2)  ·  Digestive System Diseases (1)  ·  Hepatitis B, Chronic (1)  ·  Liver Diseases (1)

Broader conditions

Chronic Disease (9)  ·  Disease Attributes (9)  ·  Hepatitis, Chronic (9)  ·  Hepatitis, Viral, Human (9)  ·  Infections (9)  ·  Pathologic Processes (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  RNA Virus Infections (9)  ·  Virus Diseases (9)  ·  Digestive System Diseases (8)  ·  Liver Diseases (8)  ·  Hepatitis (7)  ·  Hepatitis D (5)  ·  Blood-Borne Infections (2)  ·  Communicable Diseases (2)

Interventions

bulevirtide (3)  ·  peginterferon alfa-2a (2)  ·  Ritonavir (1)  ·  Tenofovir (1)  ·  lonafarnib (1)  ·  myrcludex-B (1)  ·  peginterferon alfa-2b (1)

Sponsors

Hoffmann-La Roche (2)  ·  Vir Biotechnology, Inc. (2)  ·  Gilead Sciences (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Mirum Pharmaceuticals, Inc. (1)  ·  Shanghai HEP Pharmaceutical Co., Ltd. (1)  ·  Soroka University Medical Center (1)

Countries

Germany (4)  ·  Romania (4)  ·  Italy (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  France (2)  ·  New Zealand (2)  ·  Spain (2)  ·  Turkey (Türkiye) (2)  ·  United States (2)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  Georgia (1)  ·  Israel (1)

Top investigators

Junqi Niu, Professor (1)  ·  Ohad Etzion, MD (1)  ·  Yanhang Gao (1)

Results publications

PMID 41586499, PMID 30833068, PMID 37120031, PMID 38340811, PMID 39009085, PMID 39648559, PMID 41405233, PMID 41966308

NIH funding

2019 (1)